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CHAPTER 1 
1.0 INTRODUCTION 
[1-5] 
             Analytical chemistry, like other areas of chemistry and science, has gone through 
drastic changes and growth. Analytical chemistry may defined as the “Science and art of 
determining the composition of materials in terms of the elements or compounds 
contained”. In analytical chemistry it is of prime importance to gain information about the 
qualitative and quantitative composition of substances and chemical species, that is to find 
out what a substance is composed of and exactly how much .                                                                   
 Analytical method is a specific application of a technique to solve an analytical 
problem. The use of instrumentation is an exciting and fascinating part of chemical analysis 
that interacts with all areas of chemistry and with many other areas of pure and applied 
science. Analytical instrumentation plays an important role in the production and 
evaluation of new products and in the protection of consumers and the environment. This 
instrumentation provides the lower detection limits required to assure safe foods, drugs and 
water. The manufacture of materials, whose composition must be known precisely such as 
substances used in integrated circuit chips, is monitored by analytical instruments.          
               Instrumental or physicochemical methods are based on the theory of relations 
between the content and the corresponding physicochemical and physical properties of the 
chemical system being analyzed.  Changes in the system properties are either detected or 
recorded through the measurement of current, electrode potential, electrical conductivity, 
optical density, refractive index etc. with suitable and sensitive instruments. In instrumental 
analysis physical property of substance is measured to determine its chemical composition.   
 Measurements of physical properties of analyte such as conductivity, electrode 
potential, light absorption  or emission, mass to charge ratio, and fluorescence, began to be 
used for quantitative analysis of variety of inorganic and biochemical analyses. Highly 
efficient chromatographic and electrophoretic techniques began to replace distillation, 
extraction, and precipitation for the separation of components of complex mixtures prior to 
their qualitative or quantitative determination.       
 
 
 
 
    
 
 
2 
                                                                       
 
 
1.1 PRINCIPAL TYPES OF CHEMICAL INSTRUMENTATION                            
 Spectroscopic Techniques  
1) Ultraviolet & visible Spectrophotometry  
2) Fluorescence & Phosphorescence Spectrophotometry  
3) Atomic Spectrometry (Emission & absorption) 
4) Infrared Spectrophotometry 
5) Raman Spectroscopy 
6) Radiochemical techniques including activation analysis 
7) Nuclear Magnetic Resonance Spectroscopy 
8) Electron Spin Resonance Spectroscopy 
 
 Electrochemical Techniques 
1) Potentiometry  
2) Volta metric techniques 
3) Amperometric techniques  
4) Coulometry 
5) Electrogravimetry  
6) Conductance techniques 
 
 Chromatographic Techniques 
1) High Performance Liquid Chromatography 
2) Gas chromatography 
 
 Miscellaneous Techniques  
1) Thermal analysis 
2) Mass Spectrometry  
3) Kinetic techniques 
 
 Hyphenated Techniques 
1) GC-MS  (Gas Chromatography – Mass Spectrometry) 
2) ICP-MS (Inductively Coupled Plasma - Mass Spectrometry) 
3) GC-IR    (Gas Chromatography – Infrared Spectroscopy) 
4) MS-MS   (Mass Spectrometry – Mass Spectrometry) 
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1.2 INTORDUCTION TO CHROMATOGRAPH 
[6-7] 
Chromatography was first invented by Michael Tswett, a Russian botanist in 1906 
in Warsaw for the separation of colored substance into individual component.  
Chromatography is defined as a procedure by which solutes are separated by a 
dynamic differential migration process in a system consisting of two or more phases, 
one of which moves continuously in a given direction and in which the individual 
substances exhibit mobilities by reason of differences in adsorption, partition, 
solubility, vapour pressure, molecular size or ionic charge density. The individual 
substances thus obtained can be identified or determined by analytical methods. 
Chromatography was invented nearly 100 years ago, but it is only in the past few 
years that the development of the technique and associated instrumentation has reached a 
level that might be called the ‘steady state’. 
Separation Process: 
The Chromatographic method of separation, in general, involves the following steps: 
 Adsorption or retention of substance or substances on the stationary phase. 
 Separation of the adsorbed substances by the mobile phase. 
 Recovery of the separated substances by the continuous flow of the mobile phase. 
 Qualitative and quantitative analysis of the eluted substances. 
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 1.2.1   DIFFERENT FORMS OF CHROMATOGRAPH 
The different forms of chromatography are shown in Fig. 1. 
                                    CHROMATOGRAPHY 
                                                        
 
Gas Chromatography                                      Liquid Chromatography 
                        Gas –Liquid                                                   
                    Chromatography 
        
                         Gas- Solid                                                           
                                   Chromatography  
                                    
                                             
               Adsorption              Partition                Size Exclusion     Affinity            Ion exchange     
 
                             
 
 
Fig 1: Different Forms Of Chromatography 
1.3 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
8 
High performance Liquid Chromatography (HPLC), also known as high pressure 
liquid chromatography, is essentially a form of column Chromatography in which the 
stationary phase consists of small particle (3-50 ȝm) packing contained in a column with a 
small bore (2-5mm), one end of which is attached to source of pressurized liquid eluent  
(Mobile phase).           
In High Performance Liquid Chromatography, the mobile as well as the stationary 
phase compete for the distribution of the sample components. In case of HPLC, separation 
is based on: 
 
 Partition      : Separation due to differences in solubility characteristics between 
                         two phases.  
Competition bet
n
 
liquid mobile 
phase and solid 
adsorbent 
Competition bet
n
 
liquid mobile 
phase and liquid 
stationary phase 
 
Molecular 
sieving 
Lock & Key 
mechanism 
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 Adsorption     : Separation due to difference in interaction with the surface of the         
                         stationary phase. 
 Ion Exchange: Due to differences in the affinity of ions for the ion exchanger. 
 Size Exclusion: Due to differences in molecular weight and size of the molecules         
                           to be separated.  
Today, HPLC is the most widely used analytical separation method. The method is 
popular because it is non-destructive and may be applied to thermally labile compounds 
(unlike GC); it is also very sensitive technique since it incorporates a wide choice of 
detection methods. With the use of post-column derivatization methods to improve 
selectivity and detection limits, HPLC can easily be extended to trace determination of 
compounds that do not usually provide adequate detector response. The wide applicability 
of HPLC as separation method makes it a valuable separation tool in scientific fields. 
1.3.1    MODES OF SEPARATION IN HPLC  
 
There are different modes of separation in HPLC. They are  
 Normal Phase Chromatography (NPC);  
 Reversed Phase Chromatography (RPC);  
 Ion Exchange Chromatography;  
 Ion Pair Chromatography;  
 Size Exclusion Chromatography; and  
 Affinity Chromatography 
1.3.2 COMMONLY USED METHOD IN HPLC  
1) Normal phase chromatography  
  For a polar stationary bed like silica we need to choose a relatively non polar 
mobile phase. This mode of operation is termed as Normal phase chromatography. Here 
the least polar component elutes first, and increasing the mobile phase polarity leads to 
decrease in elution time. Isopropanol, diisopropyl ether and acetic acid are used as 
modifiers or tail reducers. Nonpolar solvents like Pentane, Hexane, Iso Octane, 
Cyclohexane, etc. are more popular. It is extremely important to control the water content 
of the stationary phase while using silica columns. Variation in moisture content of silica 
leads to variation in retention times. Therefore, it is a common practice to saturate the 
mobile phase with water before using it as eluent in Normal phase chromatography. It is 
mainly used for separation nonionic, nonpolar to medium polar substances.  
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2) Reverse phase chromatography   
   For hydrocarbon type or nonpolar stationary phase, we need to choose a polar 
mobile phase. This mode of partition chromatography is called as Reverse phase 
chromatography. Here the most polar component elutes first. Increasing mobile phase 
polarity leads to decrease in elution time. Common solvents used in this mode include 
Methanol/Acetonitrile/Isopropanol etc. Control of pH is another way to control resolution. 
In the case of an aromatic acid, a low pH buffer will suppress the ionization, and will 
increase the capacity factor, while with a high pH buffer, the capacity factor will decrease. 
Small amounts of modifiers like sodium phosphate/ sodium acetate reduce peak tailing, and 
increase the separation efficiencies. Mostly used for separation of ionic and polar 
substances.  
3) Ion- Pair Chromatography
  
 
Ion-pair and RP- HPLC have several similar features. The column and mobile phase 
used for both these separation techniques are similar, differing mainly in the addition of an 
ion-pair reagent to the mobile phase for ion-pair chromatography (IPC). If RPC method 
development is unable to provide an adequate separation due to poor band spacing, IPC 
provides selectivity option.   
 1.3.3 Elution Techniques 
a) Isocratic elution: 
A separation in which the mobile phase composition remains constant 
throughout the procedure is termed isocratic (meaning constant composition). 
b) Gradient elution: 
The mobile phase composition does not have to remain constant. A separation 
in which the mobile phase composition is changed during the separation process is 
described as a gradient elution. One example is a gradient starting at 10% methanol and 
ending at 90% methanol after 20 minutes. The two components of the mobile phase are 
typically termed "A" and "B"; A is the "weak" solvent which allows the solute to elute 
only slowly, while B is the "strong" solvent which rapidly elutes the solutes from the 
column. Solvent A is often water, while B is an organic solvent miscible with water, 
such as acetonitrile, methanol, THF or isopropanol. 
In isocratic elution, peak width increases with retention time linearly according 
to the equation for N, the number of theoretical plates. This leads to the disadvantage 
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that late-eluting peaks get very flat and broad. Their shape and width may keep them 
from being recognized as peaks. 
Gradient elution decreases the retention of the later-eluting components so that 
they elute faster, giving narrower (and taller) peaks for most components. This also 
improves the peak shape for tailed peaks, as the increasing concentration of the organic 
eluent pushes the tailing part of a peak forward. This also increases the peak height (the 
peak looks "sharper"), which is important in trace analysis. The gradient program may 
include sudden "step" increases in the percentage of the organic component, or different 
slopes at different times - all according to the desire for optimum separation in 
minimum time.   
In isocratic elution, the selectivity does not change if the column dimensions 
(length and inner diameter) change - that is, the peaks elute in the same order. In 
gradient elution, the elution order may change as the dimensions or flow rate change. 
  The driving force is originated in reversed phase chromatography in the high 
order of the water structure. The role of the organic mobile phase is to reduce this high 
order by reducing the retarding strength of the aqueous component. 
1.3.4 HPLC Instrumentation  
  A liquid chromatography consists of a reservoir containing the mobile phase, a 
pump to force the mobile phase through the system at high pressure, an injector to 
introduce the sample into the mobile phase, a chromatographic column, a detector, and a 
data collection device such as a computer, integrator, or recorder. Short, small bore 
columns containing densely packed particles of stationary phase provide for the rapid 
exchange of compounds between the mobile and stationary phases. In addition to receiving 
and reporting detector output, computers are used to control chromatographic settings and 
operations, thus providing for long periods of unattended operations.
9-10
 
 
The different parts of HPLC system are schematically shown in the Fig.  2. 
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Fig. 2: High Performance Liquid Chromatography (Schematic). 
 
1.4 HPLC METHOD DEVELOPMENT 
1.4.1 METHOD DEVELOPMENT
9-10
 
Today the development of a method of analysis is usually based on prior art or 
existing literature, using the same or quite similar instrumentation. It is rare today that an 
HPLC based method is developed that does not in some way relate or compare to existing, 
literature based approaches. The development of any new or improved method usually 
tailors existing approaches and instrumentation to the current analyte, as well as to the final 
needs or requirements of the method. 
 Method development usually requires selecting the method requirements and 
deciding on what type of instrumentation to utilize and why. In the development stage, 
decisions regarding choice of column, mobile phase, detectors, and method of quantitation 
must be addressed. In this way, development considers all the parameters pertaining to any 
method. 
 
There are several valid reasons for developing new method of analysis: 
 There may not be suitable method for a particular analyte in the specific sample matrix. 
 Existing method may be inaccurate, artifact , and /or contamination prone, or they may 
be unreliable (have poor accuracy or precision) 
 Existing methods may be too expensive, time consuming or energy intensive, or they 
may not be easily automated. 
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 Existing methods may not provide adequate sensitivity or analyte selectivity in samples 
of interest. 
 Newer instrumentation and techniques may have evolved that provide opportunities for 
improved methods, including improved analyte identification or detection limits, 
greater accuracy or precision , or better return on investment. 
 There may be a need for an alternative method to confirm for legal or scientific reasons 
analytical data originally obtained by existing methods. 
 
Separation Goals And Steps Involved In HPLC Method Development 
    The major steps involved in the methods development are shown in the Fig.  3 and 
the separation goals in HPLC method development are shown in Table 1. 
 
 
Goal Comment 
Resolution  Precise and rugged quantitative analysis requires that Rs be greater 
than 1.5. 
Separation time  <5-10 min is desirable for routine procedures. 
Quantitation  ≤2% (1 SD) for assays; ≤5% for less-demanding analyses; ≤15% 
for trace analyses. 
Pressure <150 bar is desirable, <200 bar is usually essential  
(new column assumed). 
Peak height  Narrow peaks are desirable for large signal/ noise ratios. 
Solvent consumption Minimum mobile-phase use per run is desirable. 
Table 1: Separation Goals In Hplc Method Development 
 
 
 
 
 
 
 
 
 
10 
                                                                       
 
 
HPLC method development is based on few basic steps includes:
 11-12 
 
 
 
 
 
 
  
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
Fig 3: Steps in HPLC Method Development 
  Once the instrumentation has been selected, based on the criteria suggested above, 
it is important to determine “Analyte Parameters” of interest. To develop a method it is 
necessary to consider the properties of analytes of interest that may be advantageous to 
establish optimal ranges of analyte parameter values. It is important that method 
development may be performed using only analytical standards that have been well 
identified and characterized, and whose purity is already known. Such precautions will 
prevent problems in the future and will remove variables when one is trying to optimize or 
improve initial conditions during method development. 
 
1. Information on sample, define 
separation goals 
2. Need for special HPLC procedure, 
sample pre-treatment, etc? 
3. Choose detector and detector setting  
4. Choose LC method; preliminary run, 
estimate best separation conditions 
5. Optimize separation conditions 
6. Check for problems or requirement for 
special procedures 
7a. Recover 
purified 
material 
7c. 
Qualitative 
method
7b. Quantitative calibration
8. Validate method for release to routine 
laboratory 
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1.4.2 Step-by-Step HPLC method development
13-16 
  
Documentation starts at the very beginning of the method development process, a 
system for full documentation of the development studies must be established. All data 
relating to these studies must be established. All data relating to these studies must be 
recorded in laboratory notebooks or an electronic database.
 
Different steps used in method development are: 
 
1. Literature collection 
 Search the literature (USP, EP, JP, IP, Chromatography journals, patents, internet 
etc.) for available/ existing HPLC methods for the given molecule or molecules 
having similar structures. 
 Check the suitability of reported literature methods and see if the requirements are 
met. If required, modify the method to meet the requirements such as resolution of 
possible impurities as per the synthetic process. 
 Specify the components to be evaluated in the HPLC method considering all the 
possible impurities that can be present in drug substance which could be 
intermediates, raw materials, process related impurities and degradants. 
 Collect samples, standards and all possible impurities of each stage, if available. 
 
2. Chemical structure and other information 
 Obtain information on analyte solubility, the pKa values (if available) and functional 
groups since it is a prerequisite for effective method development. 
 Based on the structure and the functional group present it can be determined whether 
the compound is basic, acidic or neutral. 
3. Polarity 
 Depending on the solubility and nature (acid/base/ionic/non-ionic) of the molecule 
select the appropriate mode given below. 
 Reversed phase chromatography - acids, bases and non-ionic sample 
 Ion-pair chromatography - ionic samples. 
 Ion exchange chromatography - ionic samples.  
 Normal phase chromatography - isomers, non-polar/non-ionic samples, chiral 
molecules. 
 Size exclusion chromatography - high molecular weight samples such as proteins. 
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4. pH/pka Value of compounds  
 Based on pH/pKa values, the nature of the compound (acidic, basic or neutral in 
nature) and polarity of the compound can be assumed. 
Note: if the compound is acidic, acidic mobile phase is preferable. For a basic 
compound, low pH and basic mobile phase is preferable. For a neutral compound 
neutral mobile phase is suitable. 
5. Solubility 
 Check the solubility of the sample in solutions like mobile phase, mobile phase 
organic mixtures, water-organic mixtures and mixtures of acids like perchloric acid, 
phosphoric acid etc. 
Note: If the analyte is soluble in polar solvents like water, methanol, chloroform, 
acetonitrile or tetrahydrofuran, the method development should be initiated in 
reversed phase chromatography. If the analyte is soluble in non-polar solvents like 
ethyl acetate, n-hexane, dioxane etc. then the method development can be initiated 
in normal phase chromatography. 
6. Column selection 
 Reversed phase 
Column containing C4, C8, C18, Cyano and phenyl, amino stationary phases 
comes under reversed phase category and can be used against a more polar mobile 
phase. The retention of non-polar compounds increases as the length of the alkyl 
ligand (C4, C8, C18 etc.) increases. 
 Normal phase 
Columns containing cyano, phenyl and silica stationary phases come under 
normal phase category and are used against non-polar mobile phases. 
The impact of the bonded phase, internal diameter, particle surface area, pore 
volume and size of theoretical plates, peak symmetry, selectivity and resolution 
should be evaluated. 
7. Selection of detector 
 Select a suitable detection technique based on the structure and nature of the 
molecule. 
 UV detectors :compounds having chromophores 
 Fluorescence Detector  : Compounds having Fluorescence properties 
 Electrochemical Detector : Easily oxidizable compounds 
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 RI Detector: Universal Detector: but cannot be used with gradient elution. This 
detector is used   for compounds which do not contain chromophores. 
  ELSD: Universal Detector, but can be used with gradient analysis with higher 
sensitivity.                                                   
8. Mobile phase selection 
  Choice of solvents for reversed phase chromatography 
The solvents like Water, Methanol, Acetonitrile, Tetrahydrofuran, Isopropyl   
alcohol, Ethanol etc. 
Note: when THF is used as mobile phase component, the content should not be 
more than 20%. 
  Organic modifiers  
Triethylamine, Diethyl amine, Trifluoroacetic acid, Phosphates, Perchlorates, 
Chlorides, Bromides, Nitrates etc. 
   Choice of buffering agent 
Phosphates of sodium, potassium, ammonium etc, perchlorates of ammonium, 
sodium, potassium etc., ammonium acetate etc.  Buffering agent should be selected 
appropriately in their buffering range to maintain a constant pH of the mobile phase. 
  Choice of solvents for normal phase chromatography 
Solvents like Isopropyl alcohol, Ethanol, n-hexane, Dioxin, Chloroform etc. 
Organic modifiers used with normal phase chromatography: Triethylamine, Diethyl 
amine, Trifluoroacetic acid, Formic acid and Acetic acid. 
  Ionic compounds 
Compounds which are highly polar or ionic in nature do not retain on reversed 
phase columns and have poor peak symmetry. For such compounds the method should be 
developed either in ion exchange chromatography mode or ion pair chromatography is 
preferred because it can be run on the conventional reversed phase columns such as C8, 
C18 etc. with mobile phase additives.  
  Ion pair reagents (sodium lauryl Sulphate, heptane Sulphonic acid, Tetra butyl 
ammonium hydroxide, etc.) of concentrations 0.001%-0.5% can be added to the mobile 
phase to get optimum retention, peak symmetry and separations. 
Note: Concentrations more than specified range should be justified for acidic 
compounds cationic ion pair reagents like tetra butyl ammonium hydrogen sulphate, tetra 
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methyl ammonium bromide, sodium per chlorate, can be used as additives in the mobile 
phase at suitable pH. 
    For basic compounds, anionic ion pair reagents like sodium salt of butane, pentane, 
hexane or octane sulphonic acid, per chlorates etc. can be used as additives in the mobile 
phase at suitable pH. 
9. Instrument set up and Initial Studies: 
a) Set up the required instrumentation. Verify installation and operational and 
performance qualifications of instrumentation using laboratory standard operating 
procedures (SOP’s). 
b) Always use new consumables (e.g. solvents filters and gases). For example never 
start method development on an HPLC column that has been used before. 
c) Prepare the analyte standard in a suitable injection / introduction solution and in 
known concentration and solvents. It is important to start with authentic, known 
standards rather than with a complex sample matrix. If the sample is extremely 
close to the standard (eg. Bulk drug), then it is possible to start work with actual 
sample. 
d) Begin the analysis using the analytical conditions described in the existing 
literature. 
e) Evaluate feasibility of method with regard to the analytical figures of merit obtained 
 
10. Optimization 
During optimization change one parameter at a time, and isolate set of conditions, 
rather than use a trial and error approach. . Work from an organized, methodical plan, and 
document every step (Keep a lab notebook) in case of dead ends. 
 
11. Demonstration of analytical figures of merit 
  Document the originally determined analytical figures of merit [limit of quantitation 
(LOQ), limit of detection (LOD), linearity, time per analysis, cost, sample preparation etc]     
 
12.  Evaluation of method development with actual samples 
Ensure that the sample solution leads to unequivocal, absolute identification of the 
analyte peak of interest apart from all other matrix components. 
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13. Determination of percent recovery of actual sample and demonstration of 
quantitative sample analysis 
Determine percent recovery of spiked, authentic standard analyte into sample 
matrix that is shown to contain no analyte. Show   reproducibility of  recovery (average ± 
standard deviation) from sample to sample and whether recovery has been optimized. It is 
not necessary to obtain 100% recovery as long as the results are reproducible and known 
with a high degree of certainty. 
1.4.3 Chromatographic Parameters: 
a) RETENTION TIME 
b) RETANTION VOLUME 
c) SEPERATION FACTOR 
d) CAPACITY FACTOR 
e) ASYMMETRIC FACTOR 
f) THEORETICAL PLATES 
g) RESOLUTION 
 
a) RETENTION TIME (Rt): 
It is the difference in time between the point of injection and the appearance 
of peak maxima. Retention time is the time required for 50 % of a component to be 
eluted from a column. It is measured in minutes or seconds. 
b) RETENTION VOLUME (Vr): 
It is the volume of carrier gas required to elute 50% of the component from 
the column.          
R.V=R .T  Flow rate 
c) SEPERATION FACTOR: 
Separation factor is the ratio of partition - co-efficient of the two 
components to be separated. 
                                                    Kb        Ka               (tb – t o) 
                                                  S =         =               =                         
                                                     Ka        Kb              (ta – t o) 
Where,       to  = Retention time to unretained substance 
Kb,Ka = Partition Coefficient of b and a 
    tb,ta = Retention time of substance b and a 
         S = depends on liquid phase, column temperature. 
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d) CAPACITY FACTOR: 
It is generally required to be calculated by the difference in the retention 
time of main peak and the retention time of uracil injected to the retention time of 
the main peak. 
                                             K’  =    Rt-Ru 
                                                           Rt 
Where,  
R t :   is the retention time of main peak, 
R u :  is the retention time of uracil. 
K’  :  is the capacity factor  
It is one of the important factor need to be determined while performing method 
development of multi formulation, it should be always less than 2. 
e) ASSYMETRIC FACTOR: 
A chromatographic peak should be symmetrical about its center and said to 
follow Gaussian distribution. But due to some factors, the peak is not symmetrical 
and shows tailing and fronting.  
FRONTING: It is due to the saturation of stationary phase and can be avoided by using 
less quantity of sample. 
TAILING: It is due to more active adsorption sites and can be eliminated by support 
pretreatment, more polar mobile phase, increasing the amount of liquid phase. 
f) THEORETICAL PLATES (PLATE THEORY): 
A theoretical plate is an imaginary or hypothetical unit of a column where 
distribution of solute between stationary and mobile phase has attained equilibrium. 
A theoretical plate can also be called as a functional unit of the column. 
g) RESOLUTION (Rs): 
Resolution is measure of the extent of separation of the two components and 
the base line separation achieved. 
1.5 METHOD VALIDATION 
17-18 
 
Validation is defined as follows by different agencies 
Food and Drug administration (FDA): Establishing documentation evidence, 
which provides a high degree of assurance that specific process, will consistently 
produce a product meeting its predetermined specification and quality attributes. 
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World Health Organization (WHO): Action of providing that any procedure, 
process, equipment, material, activity, or system actually leads to the expected results. 
European Committee (EC): Action of providing in accordance with the 
principles of good manufacturing practice, that any procedure, process, equipment 
material, activity or system actually lead to the expected results.  In brief validation is 
a key process for effective Quality Assurance. 
Analytical method validation 
Analytical monitoring of a pharmaceutical product or of specific ingredients 
within the product is necessary to ensure its safety, efficacy throughout all phases of 
its shelf life.  Such monitoring is in accordance with the specifications elaborated 
during product development.   
Analytical method validation is the corner stone of process validation without 
a proven measurement system it is impossible to confirm whether the manufacturing 
process has done what it purports to do. All new analytical methods developed are 
validated. 
Steps followed for validation procedures 
1. Proposed protocols or parameters for validations are established 
2. Experimental studies are conducted 
3. Analytical results are evaluated 
4. Statistical evaluation is carried out 
5. Report is prepared documenting all the results 
1.5.1 VALIDATION PARAMETERS 
19-25 
Analytical methods are required for the identification, batch analysis and storage 
stability data for active constituents of Pharmaceutical product, and for post-registration 
compliance purposes. Analytical method development as a first step is carried out to ensure 
that the API used and the dosage forms that are developed and manufactured for human 
consumption are meeting the regulated quality norms. Every newly developed method must 
be validated prior to sample analysis. Validation must also be repeated if a parameter has 
been modified or if the validation was strongly performed in another laboratory, to ensure 
that the methods are transferable. A verification is necessary if the analyst or instrument 
have been changed, or if the sample type has been modified. 
The objective of validation of an analytical method is to demonstrate that the 
procedure, when correctly applied, produces results that are fit for purpose. Method 
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validation is a practical process designed and experimentally carried out to ensure that an 
analytical methodology is accurate, specific, reproducible and rugged over the specified 
range of analysis. Validation provides both assurance and reliability during normal use and 
documented evidence that the method is ‘fit for purpose’. 
Method validation ensures the validity of a measurement before it is carried out and 
is essential part of quality assurance procedures. The process of method validation 
provides information on the critical factors affecting the method output, thus enabling  
suitable quality control procedures to be implemented to ensure data quality. The extent of 
method validation will vary with applications, sector and regulatory compliance. 
Typical validation characteristics which should be considered are listed below  
 Accuracy 
 Precision 
 Specificity 
 Detection limit  
 Quantitation limit  
 Linearity 
 Range 
 Robustness 
 Ruggedness 
1.5.2 ICH VALIDATION PARAMETERS 
19,20
 
Table 2 :  Data Elements Required For Validation According To ICH 
 - signifies that this characteristic is not normally evaluated 
Type of analytical 
procedure 
Identification 
Testing  for impurities Assay-dissolution 
(measurement only) 
- content/potency Characteristics Quantitation Limit 
Accuracy - + - + 
Precision 
Repeatability 
Interm. Precision 
 
- 
- 
 
+ 
(1) 
 
- 
- 
+ 
+ 
(1) 
Specificity (2) + + + + 
Detection Limit - (3) + - 
Quantitation Limit - + - - 
Linearity - + - + 
Range - + - + 
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 + signifies that this characteristic is normally evaluated 
 (1) In cases where reproducibility has been performed, intermediate 
precision is not needed 
 (2) Lack of specificity of one analytical procedure could be compensated by 
other supporting analytical procedure(s) 
 (3) May be needed in some cases 
 
1.5.3 USP VALIDATION PARAMETERS 
19,20
       
Analytical 
Performance 
Characteristics 
Category I 
Category II
 
Category III Category IV
Quantitative 
Limit 
Tests 
Accuracy Yes Yes * * No 
Precision Yes Yes No Yes No 
Specificity Yes Yes Yes * Yes 
Detection Limit No No Yes * No 
Quantitation 
Limit 
No Yes
 
No
 
*
 
No
 
Linearity Yes Yes No * No
Range Yes Yes * * No
* May be required, depending on the nature of the specific test. 
Table 3: Data Elements Required for Validation According to USP 
 
1) Accuracy 
 The accuracy of an analytical method is defined as the degree to which the 
determined value of analyte in a sample corresponds to the true value. Accuracy may be 
measured in different ways and the method should be appropriate to the matrix. The 
accuracy of an analytical method may be determined by any of the following ways:  
 Analyzing a sample of known concentration and comparing the measured value to the 
‘true’ value. However, a well characterized sample (e.g. reference standard) must be 
used.  
  Spiked-placebo (product matrix) recovery method. In the spiked-placebo recovery 
method, a known amount of pure active constituent is added to formulation blank 
(sample that contains all other ingredients except the active ingredient), the resulting 
mixture is assayed, and the results obtained are compared with the expected result.  
 Standard addition method. In the standard addition method, a sample is assayed, a 
known amount of pure active constituent is added, and the sample is again assayed. 
 
 
20 
                                                                       
 
 
The difference between the results of the two assays is compared with the expected 
answer.  
 In both methods (spiked-placebo recovery and standard addition method), recovery 
is defined as the ratio of the observed result to the expected result expressed as a 
percentage. 
 The accuracy of a method may vary across the range of possible assay values and 
therefore must be determined at several different fortification levels. The accuracy should 
cover at least 3 concentrations (50%, 100% and 150%) in the expected range.  
 Accuracy may also be determined by comparing test results with those obtained 
using another validated test method.  
Acceptance criteria: 
  The expected recovery depends on the sample matrix, the sample processing 
procedure and on the analyte concentration. The mean % recovery should be within the 
following ranges: For assay: 98%-102% 
 
2) Precision 
The precision of an analytical procedure expresses the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple sampling of 
the same homogeneous sample under the prescribed conditions. 
Precision may be considered at three levels:  
 System Precision (Repeatability) 
 Method Precision (Reproducibility) 
 Intermediate precision (Ruggedness) 
The precision of an analytical procedure is usually expressed as the variance, 
standard deviation or coefficient of variation of a series of measurements. A minimum of 6 
replicate sample determinations should be made together with a simple statistical 
assessment of the results, including the percent relative standard deviation. The following 
levels of precision are recommended.  
Acceptance criteria: For an assay the %RSD should be NMT 2% 
 
3) Specificity 
21-23
  
It signifies the instruments, ability to measure or identify the analyte without any 
interference from sample matrix, impurities, precursors or degradation product. 
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Forced degradation
 
Forced degradation provides useful information about the degradation pathways and 
degradation products during the product storage. The information thus obtained will 
facilitate pharmaceutical development in areas such as formulation development, 
manufacturing, and packaging, where knowledge of chemical behavior can be used to 
improve the quality of drug product. 
HPLC methods should be able to separate, detect, and quantify the various drug-
related degradants that can form on storage or manufacturing, plus detect and quantify any 
drug-related impurities that may be introduced during synthesis. Forced degradation studies 
(chemical and physical stress testing) of new chemical entities and drug products are 
essential to help develop and demonstrate the specificity of such stability-indicating 
methods. In addition to demonstrating specificity, forced degradation studies can be used to 
determine the degradation pathways and degradation products of the APIs that could form 
during storage, and facilitate formulation development, manufacturing, and packaging. 
Procedures for the preparation of specific degradation products needed for method 
validation often emerge from these studies. 
For marketing applications, current FDA and ICH guidance recommends inclusion 
of the results, including chromatograms of stressed samples, demonstration of the stability 
indicating nature of the analytical procedures, and the degradation pathways of the API in 
solid state, solution, and drug product. The chemical structures of significant degradation 
products and the associated procedures for their isolation and/or characterization are also 
expected to be included in the filing. The experimental protocol for performing forced 
degradation studies will depend on the active ingredients and formulation involved because 
the chemistry of each compound is different. In general, a target of approximately 10-30% 
degradation of the API during forced degradation, or exposure to energy in slight excess of 
what is typically used in accelerated storage is recommended. In this way, the “worst-case” 
degradation products can be studied. The following will provide some suggestions for 
performing forced degradation studies based upon available guidance from the ICH and 
FDA. 
Stress testing is likely to be carried out on a single batch of the drug substance. The 
testing should include the effect of temperatures [in 10°C increments (i.e., 50°C, 60°C) 
above that for accelerated testing], humidity (i.e., 75% relative humidity or greater) where 
appropriate, oxidation, and photolysis on the drug substance. The testing should also 
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evaluate the susceptibility of the drug substance to hydrolysis across a wide range of pH 
values when in solution or suspension.
 
The stress studies should assess the stability of the drug substance in different pH 
solutions, in the presence of oxygen and light, and at elevated temperatures and humidity 
levels. The guidance does not specify pH, temperature ranges, specific oxidizing agents, or 
conditions to use, the number of freeze-thaw cycles, and so on. In general, values anywhere 
between 5% to 20% degradation of the drug substance have been considered as reasonable 
and acceptable for validation of chromatographic assays. 
 
Different forced degradation conditions to be used for drug substances & products 
16
 
 
Fig 4: Different Forced Degradation Conditions To Be Used For Drug Substances & Products 
However, for small pharmaceutical molecules for which acceptable stability limits 
of 90% of label claim is common, pharmaceutical scientists have agreed that approximately 
10% degradation is optimal for use in analytical validation. In designing forced degradation 
studies, it must be remembered that more strenuous conditions than those used for 
accelerated studies (25°C/60% RH or 40°C/75% RH) should be used. 
It must be noted that a forced degradation study is a “living process” and should be 
done along the developmental time line as long as changes in the stability-indicating 
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methods, manufacturing processes, or formulation changes are ongoing. Forced 
degradation is only considered complete after the manufacturing process is finalized, 
formulations established, and test procedures developed and qualified. 
At a minimum, the following conditions should be investigated:  
1. Acid and base hydrolysis 
2. Hydrolysis at various pH 
3. Thermal degradation 
4. Photolysis degradation 
5. Oxidation degradation. 
4) Detection limit 
 The detection limit of an analytical procedure is the lowest amount of an analyte in 
a sample that can be detected, but not necessarily quantitated as an exact value.  
  The LOD may be determined by the analysis of samples with known 
concentrations of analyte and by establishing the minimum level (lowest calibration 
standard) at which the analyte can be reliably detected. The lowest calibration standard 
which produces a peak response corresponding to the analyte should be measured ‘n’ times 
(normally 6-10). The average response (X) and the standard deviation (SD) calculated.  
The LOD = 3.3 * SD/ Slope of Calibration curve 
SD = Standard Deviation  
5) Quantitation limit 
 The limit of quantitation is the lowest amount of the analyte in the sample that can 
be quantitatively determined with defined precision under the stated experimental 
conditions. The limit of quantitation is a parameter of quantitative assays for low levels of 
compounds in sample matrices and is used particularly for the determination of impurities 
and/or degradation products or low levels of active constituent in a product. The LOQ may 
be determined by preparing standard solutions at estimated LOQ concentration (based on 
preliminary studies). The solution should be injected and analyzed ‘n’ times (normally 6-
10). The average response and the standard deviation (SD) of the n results should be 
calculated and the SD should be less than 20%. If the SD exceeds 20%, a new standard 
solution of higher concentration should be prepared and the above procedure repeated.  
 The LOQ = 10 * SD/ Slope of Calibration curve 
 SD = Standard Deviation  
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6) Linearity 
 The linearity of an analytical method is its ability to elicit test results that are 
directly proportional to the concentration of analytes in samples within a given range or 
proportional by means of well-defined mathematical transformations. Linearity may be 
demonstrated directly on the test substance (by dilution of a standard stock solution) and/or 
by using separate weighing of synthetic mixtures of the test product components, using the 
proposed procedure.  
Linearity is determined by series injections of whose concentrations span 50-150 
percent of the expected concentration range. The response should be directly proportional 
to the concentrations of the analytes or proportional by means of a well-defined 
mathematical calculation. A linear regression equation applied to the results should have an 
intercept not significantly different from zero (0). If a significant nonzero intercept is 
obtained, it should be demonstrated that this has no effect on the accuracy of the method.  
7) Range 
The range of an analytical method is the interval between the upper and lower 
levels (including these levels) that have been demonstrated to be determined with precision, 
accuracy and linearity using the method as written. The range is normally expressed in the 
same units as the test results (e.g. percentage, parts per million) obtained by the analytical 
method. 
  For assay tests, the ICH requires the minimum specified range to be 80 to 120 
percent of the test concentration, and for the determination of an impurity, the range to 
extend from the limit of quantitation, or from 50 percent of the specification of each 
impurity, whichever is greater, to 120 percent of the specification. 
8) Robustness 
 Robustness tests examine the effect that operational parameters have on the analysis 
results. For the determination of a method’s robustness, a number of method parameters, 
for example, pH, flow rate, column temperature, injection volume, detection wavelength or 
mobile phase composition, are varied within a realistic range, and the quantitative influence 
of the variables is determined. If the influence of the parameter is within a previously 
specified tolerance, the parameter is said to be within the method’s robustness range.  
 Obtaining data on these effects helps to assess whether a method needs to be 
revalidated when one or more parameters are changed, for example, to compensate for 
column performance over time. In the ICH document, it is recommended to consider the 
evaluation of methods robustness during the development phase, and any results that are 
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critical for the method should be documented. This is not however, required as part of a 
registration. 
 
9) Ruggedness 
 Ruggedness tests examine the effect that operational parameters have on the 
analysis results. The ruggedness was determined by changing the column same 
manufacture but different lot numbers and Analyst variability and system to system 
variability. In all the ruggedness conditions the method parameters shall meet the system 
suitability criteria.  
 
10) Solution stability  
 Solution stability was determined by Preparing the samples and standard solutions 
at room temperature and inject at initially and after 1 day, 2day, 3day if possible Similarly 
Prepare the mobile phase and keep it at room temperature in well closed condition and inject into 
HPLC system. Evaluate the all the system suitability parameters.  
Proposed Acceptance Criteria for the Different Characteristics of Validation by ICH 
19 -20 
Characteristics Proposed Use Acceptance Criteria 
Linearity r2 ≥ 0.99, similar response ratios 
Precision-System RSD < 2 % 
Precision-Method RSD < 2 % 
Precision 
Repeatability/Reproducibility 
 
RSD ≤ 2 % 
Accuracy FDA 98-102 %, EPA 50-150 % 
Specificity No interference 
Detection Limit >2 times base line 
Quantitative Limit Signal to Noise ratio = 10:1 
Range Concentration where data can be 
reliably detected 
 
Table 4: Proposed ICH Acceptance Criteria For The Different Characteristics Of Validation 
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CHAPTER 2 
REVIEW OF LITERATURE 
 The following methods have been reported for the estimation of Naproxen and 
Esomeprazole magnesium individually and in combination with other drugs. 
1) Srinivas Ampati, et al
26
 Development And Validation Of RP-HPLC Method For 
The Simultaneous Estimation Of Naproxen Sodium And Esomeprazole magnesium 
In Pharmaceutical Tablet Dosage Form. An isocratic RP-HPLC method was 
developed and validated for the Simultaneous estimation of Naproxen sodium and 
Esomeprazole magnesium trihydrate in Pharmaceutical tablet dosage form. The 
separation was achieved by using a reversed-phase C 18 column(Thermo eletrole, 
ODS, 250mm × 4.6 mm i.d, 5ȝm) at ambient temperature with mobile phase 
consisting of Phosphate buffer (pH adjust to 3.8using OPA): Acetonitrile : 
Methanol (30:50:20v/v). The flow rate was 1.0 ml/min. Detection was carried out at 
a wavelength of 220 nm. Retention time of Naproxen sodium and Esomeprazole 
magnesium trihydrate were found tobe2.417 and 3.903min respectively. The 
proposed method was validated for selectivity, precision, linearity and accuracy. 
The assay method was found to be linear from 75-175µg/ml and 3-7µg/ml for 
Naproxen sodium and Esomeprazole magnesium trihydrate respectively. All 
validation parameters were within the acceptable range. The developed method was 
successfully applied to estimate the amount of Naproxen sodium and Esomeprazole 
magnesium trihydrate in Pharmaceutical tablet dosage form. 
2) Chandrakant Sojitra, et al
27
 Development and Validation of RP-HPLC Methods 
for Simultaneous Estimation of Naproxen and Esomeprazole magnesium Trihydrate 
in Combined Pharmaceutical Formulation. A rapid, specific, sensitive and simple 
high performance liquid chromatography was developed for simultaneous 
estimation of Esomeprazole magnesium trihydrate and Naproxen in tablet 
formulation. The separation was achieved by SUPELCO 516 C 18–DB column 
(250× 4.6 mm, particle size 5ȝm) with a mobile phase consisting of 0.01M 
phosphate buffer pH 7.5: ACN: methanol(40:50:10v/v, addition of 0.1% triethyl 
amine), at a flow  rate of 0.8 ml/min. Detection was carried out at 303 nm. 
Retention time of Esomeprazole magnesium trihydrate and Naproxen were found to 
be 4.6 and 3.2min, respectively. The linear dynamic range was 0.8-4.8ȝg/ml and 
15-90ȝg/ml for Esomeprazole magnesium trihydrate and Naproxen, respectively. 
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The method is validated for Accuracy, Precision, Ruggedness and Robustness. The 
proposed method is successfully applied for the simultaneous determination of both 
drugs in commercial tablet preparation. The results of the analysis have been 
validated statistically and by recovery studies. 
3) Deshpande.S.V, et al
28
 Development and Validation of Esomeprazole and 
Naproxen in Bulk and Tablet Dosage Form by RP-HPLC Method. A simple, rapid, 
reproducible, accurate and precise RP-HPLC method was developed for the 
quantitative simultaneous estimation of Esomeprazole and Naproxen in combined 
tablet dosage form. Esomeprazole is used as anti ulcerative and naproxen has non 
steroidal anti-inflammatory activity. The chromatographic separation of both drugs 
was achieved with 250x4.6 mm, 5 ȝm c-18 column using acetonitrile:0.01 m 
potassium dihydrogen phosphate buffer (60:40 v/v) at the flow rate of 1.0 ml/min at 
244.0 nm. The linearity range was found to be 2-30 ȝg/ml for esomeprazole and 5-
100 ȝg/ml for naproxen. The coefficient of correlation for esomeprazole and 
naproxen was found to be 0.9993 and 0.9989 respectively. The percent recoveries 
obtained for esomeprazole and naproxen were found to be 99.86 and 99.72 
respectively. The method was validated for linearity, range, precision, accuracy, 
specificity, selectivity, intermediate precision, ruggedness, robustness, stability and 
suitability. 
4) Kumar, et al
29
 Simultaneous Estimation of Esomeprazole and Naproxen in Bulk 
As well As in Pharmaceutical Formulations by Using RP-HPLC. Esomeprazole is 
used to treat gastro esophageal reflux disease. Naproxen is a Non-steroidal anti-
inflammatory drug (NSAID) used in the treatment of pain or inflammation caused 
by conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or 
menstrual cramps. A simple, precise, cost effective RP-HPLC method was 
developed and validated for the determination of both Esomeprazole and Naproxen 
in Pharmaceutical compositions. The chromatographic separation was achieved on 
a Symmetry C18 (4.6 x 150mm, 5ȝm, Make: XTerra) using a mobile phase consist 
of a mixture of phosphate buffer (pH 3) and Acetonitrile [60:40]. The flow rate of 
mobile phase was maintained 1.0 mL per minute. The wavelength chosen for 
detection was 285 nm. The retention times of Esomeprazole and Naproxen peaks 
were around 2.105 and 3.555 mins respectively. The Accuracy was calculated for 
50%, 100% and 150% and the % recovery was found to be 98.0%-100.4%. The 
method was found to be linear over the range of 5ppm to 9ppm per mL for 
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Esomeprazole 125ppm to 225ppm per mL for Naproxen. The proposed method was 
validated as per the ICH and USP guidelines. 
5) T. Manikya Rao, et al
30
 Stability indicating assay of Esomeprazole and Naproxen 
in Tablets by RP-UPLC PDA-Method. A simple fast, accurate, precise and cost 
effective isocratic RP-UPLC method is developed for simultaneous determination 
of Esomeprazole and Naproxen in tablet formulation. The retention times of 
Esomeprazole and Naproxen were found to be 0.7 and 1.2 minutes respectively. 
The method was linear over the range of 5 to 25 ppm with correlation of 0.999 for 
Esomeprazole and 125 to 625 ppm with correlation of 0.998 for Naproxen. Mean 
recovery for Esomeprazole and Naproxen were 99.82% and 99.74% respectively. 
The method found simple, accurate, precise, and linear over the given range, rugged 
and robust. 
6) Palavai Sripal Reddy, et al
31
 Stability indicating simultaneous estimation of assay 
method for naproxen and esomeprazole in pharmaceutical formulations by RP-
HPLC. Naproxen is a Non steroidal simultaneous anti inflammatory drug (NSAID) 
used in the treatment of pain or inflammation caused by conditions such as arthritis, 
ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps. 
Esomeprazole is used to treat gastro esophageal reflux disease. A simple, precise 
cost effective and stability indicating RP-HPLC method has been developed and 
validated for the determination of both Naproxen and Esomeprazole in 
pharmaceutical compositions. Separation of Naproxen and Esomeprazole from its 
potentional degradants were achieved within a shorter run time with required 
resolution, accuracy and precision thus enabling the utility of the method for routine 
analysis. The chromatographic separation was achieved on a Xterra RP-18 column 
(150 × 4.6 mm, 5ȝ) using a mobile phase consisting buffer prepared with 0.005 
mole of sodium perchlorate, 5 mL N-butyl amine in milliQ grade water with a pH 
of 8.7 which is mixed with Acetonitrile and Methanol at a flow rate of 1.5 mL per 
minute. Wavelength chosen for detection is 305 nm. The retention times of 
Naproxen and Esomeprazole peaks are around 3 and 6 minute respectively. The 
method was found to be linear over the range of 100.28 to 902.520 ȝg per mL for 
Naproxen and 9.6 to 45.6 ȝg per mL for Esomeprazole. The proposed method is 
validated as per the ICH and USP guidelines. 
7) Jain, et al
32
 The RP-HPLC method for simultaneous estimation of esomeprazole 
and naproxen in binary combination. A simple, precise, reliable, rapid, sensitive and 
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validated RP-HPLC method has been developed to determine Esomeprazole 
magnesium trihydrate (ESO) and naproxen (NAP) in synthetic mixture form. 
Materials and Methods: Chromatographic separation achieved isocratically on 
Phenomenex, Luna C18 column (150 × 4.6 mm, 5ȝ) and acetonitrile: phosphate 
buffer (pH 7.0) in the ratio of 50:50 (v/v) as the mobile phase, at a flow rate of 0.5 
ml/min. Detection was carried out at 300 nm. The retention times for NAP and ESO 
was found to be 2.67 and 5.65 min respectively. Parameters such as linearity, 
precision, accuracy, recovery, specificity and ruggedness are studied as reported in 
the ICH guidelines. Results: The method was linear in the concentration range of 
50-250ȝg/ml for NAP and 2-10ȝg/ml for ESO with correlation coefficient of 0.999 
and 0.998 respectively. The mean recoveries obtained for NAP and ESO were 
100.01% and 97.76 % respectively and RSD was less than 2. The correlation 
coefficients for all components are close to 1. Conclusions: Developed method was 
found to be accurate, precise, selective and rapid for simultaneous estimation of 
NAP and ESO. 
8) Muhammad Ashfaq, et al
33
 Development and Validation of Liquid 
Chromatographic Method for Naproxen and Esomeprazole in Binary Combination. 
The present study reports the development and validation of a simple, economic and 
sensitive HPLC method for the concurrent determination of naproxen and 
esomeprazole in pharmaceutical formulations. Isocratic chromatography was 
performed with C-18 column and mixture of phosphate buffer (pH 6.1) and 
acetonitrile in ratio of (40:60, v/v) at 1.5 mlmin-1. The eluents were monitored at 
302 nm using UV detector. The method was isocratic in the range of 9.38 to 300 
ȝgml-1 for naproxen and 0.5 to 16 ȝgml-1 for esomeprazole. Validation of the 
method was performed by testing parameters like linearity, accuracy, precision, 
robustness, specificity, LOD and LOQ values. In the specificity the drugs were 
subjected to forced degradation studies like acidic, basic, oxidative and thermal 
stresses. Both the analytes were separated within three minutes. As the method 
separates the degradation products produced during forced degradation studies from 
the active analytes so it can be used not only for regular determination of naproxen 
and Esomeprazole but also for their stability studies. 
9) Khagga Bhavyasri.V, et al
34
 Rapid Simultaneous Determination of Naproxen and 
Esomeprozole Magnesium in Combined Tablets by Validated Ultra Performance 
Liquid Chromatographic Method. A stability- indicating ultra Performance liquid 
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chromatography (UPLC) method has been developed and validated for the 
simultaneous determination of Naproxen and Esomeprazole magnesium in 
pharmaceutical preparations. An Agilent Zorbax SB Phenyl column (50X4.6mm 
i.d., 1.8ȝm particle size) was used. The mobile phase consisted of a mixture of 10 
mm Ammonium Bicarbonate (adjusted to pH 7.0 with Phosphoric acid) and 
acetonitrile in the ratio 50:50 Ultraviolet(UV) detection was performed at 215 nm. 
Total run time was 5 min; these two drugs were eluted at the retention times of 
0.766 and 1.484 min for Naproxen and Esomeprazole magnesium respectively. The 
method was validated in terms of linearity, range, specificity, accuracy, and 
precision, limit of detection (LOD) and limit of quantitation (LOQ). The linearity 
for both the drugs was found in the range of 18.7-150 ȝg mL-1of Nap and 1-8 
ȝg/mL-1. The % recoveries of Naproxen were found to be 98.2-100.2% and 
Esomeprazole magnesium were found to be 99.8-101.6%. The utility of the 
procedure is verified by its application to marketed formulations that were subjected 
to accelerated degradation studies. The method distinctly separated the drug and 
degradation products even in actual samples. The products formed in marketed 
tablet dosage forms are similar to those formed during stress studies. 
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CHAPTER 3 
DRUG PROFILE 
35
 
A) NAPROXEN  
 
S.No Parameters Details 
1 Description White or almost white, hygroscopic, crystalline 
powder. 
2 CAS No 22204-53-1 
 
 
3 
 
 
Chemical Structure 
 
 
4 Molecular Formula C14H13NaO3 
5 Molecular Mass 
252.24 g/mol 
 
6 
 
Chemical Name 
2-Naphthaleneaceticacid,6-methoxy- -methyl-
(S)-(+)-(S)-6-Methoxy- -methyl-2-
naphthaleneacetic acid 
7 Solubility Freely soluble in water, freely soluble or soluble 
in methanol, sparingly soluble in ethanol (96%). 
8 Half Life 12 to 24  hour 
 
 
9 
 
 
 
Therapeutic Uses 
Naproxen is commonly used for the reduction 
of pain, fever, inflammation, and stiffness caused 
by conditions 
including migraine, osteoarthritis, stones, 
rheumatoid, psoriatic arthritis, gout, ankylosing 
spondylitis, menstrual cramps, tendinitis, 
and bursitis, among others. It is also used  for the 
treatment of primary dysmenorrhea. 
 
10 
 
Mechanism of Action 
Naproxen works by reversibly inhibiting both 
the COX-1 and COX-2 enzymes. 
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B) ESOMEPRAZOLE MAGNESIUM 
 
S.No     Parameters Details 
1 Description  White to slightly coloured powder. 
2 CAS No 0119141-88-7 
 
 
3 
 
 
Chemical Structure  
 
4 Molecular Formula  C17H19N3O3S  
5 Molecular Mass  
345.415 g/mol 
6 Chemical Name  (S)-5-methoxy-2-[(4-methoxy-3,5-
dimethylpyridin-2-yl)-methylsulfinyl]-3H-
benzoimidazole 
7 Solubility  Esomeprazole drug is soluble in methanol, slightly 
soluble in water, insoluble in heptane. 
8 Half Life  1-1.5 Hourrs 
9 Therapeutic Uses A highly effective inhibitor of gastric acid 
secretion used in the therapy of stomach ulcers 
and zollinger-ellison syndrome. The drug inhibits 
the H
+
/K
+
-ATPase (H
+
/K
+
-exchanging ATPase) in 
the proton pump of gastric parietal cells. 
10 Mechanism of Action Esomeprazole is a proton pump inhibitor that 
suppresses gastric acid secretion by specific 
inhibition of the H
+
/K
+
-ATPase in the gastric 
parietal cell. By acting specifically on the proton 
pump, Esomeprazole blocks the final step in acid 
production, thus reducing gastric acidity. 
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CHAPTER 4 
AIM OBJECTIVE AND PLAN OF WORK 
 
AIM 
 To develop and validate the method for simultaneous estimation of Naproxen and 
Esomeprazole magnesium by RP-HPLC.  
 
OBJECTIVES 
 On literature survey it was found that Naproxen and Esomeprazole magnesium is 
estimated by HPLC and UV Spectrophotometric methods, in combination with other drugs 
in tablet and bulk dosage form.  
 However no method could be found for simultaneous estimation of Naproxen and 
Esomeprazole magnesium, and also no method was available for such estimation in the 
pharmacopoeia. In view of the need for a suitable method for routine analysis of Naproxen 
and Esomeprazole magnesium in formulations, attempts are being made to develop simple, 
precise and accurate analytical methods for simultaneous estimation of Naproxen and 
Esomeprazole magnesium and extend it for their determination in formulations.  
 The utility of the developed methods to determine the content of both drugs in 
commercial tablet is also demonstrated. Validation of the method was done in accordance 
with USP and ICH guidelines for the assay of active ingredients. The methods were 
validated for parameters like accuracy, linearity, precision, specificity, ruggedness, 
robustness, and system suitability. These methods provide means to separate the individual 
components of a mixture and simultaneously characterize and quantify the components. 
These proposed methods are suitable for the pharmaceutical analysis in analytical 
laboratories. 
 The Chromatographic methods proposed in this presume that there is a linear 
relationship between absorbance and component concentration. These methods have a 
calibration step followed by the prediction step, in which the results of the calibration step 
are used to estimate the component concentration from an unknown sample spectrum. The 
Chromatographic methods have many of full spectrum advantages. These methods are 
known to provide additional advantages that calibration can be performed by ignoring the 
concentration of all other components except the analyte of interest. These methods have 
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been successfully applied to the quantitative analysis in spectrophotometric, 
chromatographic and electrochemical data.  
In summary, the primary objective of proposed work is to:- 
 Develop new, simple, sensitive, accurate, and economical analytical methods for the 
simultaneous estimation of Naproxen and Esomeprazole magnesium. 
 Validate the proposed methods in accordance with USP and ICH guidelines for the 
intended analytical application i.e., to apply the proposed method for analysis of these 
drugs in their combined dosage form. 
 
PLAN OF WORK 
1. Selection of drug sample.  
2. Procurement of drug & other chemicals.  
3. UV-Visible Spectrophotometry  
 Determination of Ȝ max by UV Spectrophotometry. 
4. HPLC Method Development:  
 Selection of preliminary HPLC conditions  
 Selection of mobile phase  
 Selection of column     
 Selection of wavelength  
 Analysis of laboratory mixture. 
 
The steps in Method development will be as follows- 
 Analysis of standard laboratory mixture to see feasibility of the proposed methods. 
 To adopt the selected methods on marketed formulation. 
 Validation of the proposed methods. 
 
 
 
 
 
 
 
 
 
35 
                                                                       
 
 
CHAPTER 5 
5.1 METHOD DEVELOPMENT 
MATERIAL AND CHEMICALS: 
S.No. Name Grade Make Lot Number Purity 
Valid up 
to 
01 
Monobasic 
sodium 
phosphate 
AR Himedia 0000194436 98.0 % 02/2016 
02 
Dibasic sodium 
phosphate 
AR SRL T8380795 99.0 % 07/2016 
03 
Acetonitrile- 
HPLC grade 
AR Finar 118381004JN 99.8 % 09/2017 
04 
Orthophosphoric 
acid 
AR Merck CF4C640314 85.0 % 08/2017 
05 
Sodium 
Hydroxide 
AR SRL T-8382161 98.0% 12/2017 
06 Purified Water Not Applicable 
Table No. 5: Detail of Material and Chemicals 
INSTRUMENTS: 
S. No. Name Make & Model 
Date of 
Calibration 
Due date of 
Calibration 
01 
Analytical 
Balance 
Mettler Toledo XS105 
(Digital Analytical 
Balance) 
Daily calibration 
02 pH 
Hanna 
(Digital pH Meter) 
Daily calibration 
03 Sonicator PCI India 15.09.2014 14.03.2014 
04 Filter 
Nylon & PVDF 0.45 µm 
(Millipore) 
Not Applicable 
05 HPLC 
Agilent 1260 & 1290 series 
(Software-Open Lab) 
08.10.2014 02.04.2015 
06 UV 
Shimadzu UV1700 series 
(Software-UV Probe) 
  
Table No. 6: Detail of Instruments
 
COLUMN: 
S.No. Make Column Name Serial No 
01 Reliant    C18, 4.6-mm X 25cm; 5 µm  
272I340281400
3 
Table No. 7: Detail of Column 
All the glassware’s used were of borosilicate glass of class A and all the solvents and 
prepared solutions were filtered through Nylon filter 0.45u. 
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Drugs Naproxen and Esomeprazole magnesium 
Label Claim Naproxen-500 mg 
Esomeprazole magnesium-20 mg 
Manufactured by Caplin Point Unit-II, India. 
Table No. 8: Detail of Marketed Formulation 
 
S. No. Name Purity Valid Up to 
01 Esomeprazole magnesium 92.46 % 05/2015 
02 Naproxen Sodium 98.93% 12/2018 
Table No. 9 : Details Of Working Standard 
 
5.2 Study of Spectra and Selection of Wavelength: 
Preparation of Diluent: 
Methanol: Water (50:50) v/v. 
Naproxen Standard Solution (25 mcg/mL of Naproxen): 
An accurately weighed 137.0 mg of Naproxen Sodium WS (Equivalent to 125 mg 
of Naproxen) and transfer into a 50 mL volumetric flask. Add 25 mL of diluents and 
sonicate for 5 minutes to dissolve. Cool and dilute up to the volume with diluents. With 
draw 5 ml from this solution and transfer in 100 mL volumetric flask dilute up to the 
volume with mobile phase. With draw 5 ml from this solution and transfer in 25 mL 
volumetric flask dilute up to the volume with mobile phase. 
Esomeprazole Standard Solution (20 mcg/mL of Esomeprazole): 
An accurately weighed 20.65 mg of Esomeprazole magnesium WS (Equivalent to 
20 mg of Esomeprazole) and transfer into a 200 mL volumetric flask. Add 125 mL of 
diluents and sonicate for 5 minutes to dissolve. Cool and dilute up to the volume with 
diluents. With draw 5 ml from this solution and transfer in 25 mL volumetric flask dilute 
up to the volume with mobile phase. 
The solutions were scanned in the range of 600-200 nm in 1 cm cell against blank. 
The individual UV absorbance spectrum of Blank and NAP and ESO are shown in 
Fig.No.5, 6, 7 & 8. 
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Fig. No. 5: UV Spectrum of Blank 
 
Fig. No.6: UV Spectrum of Naproxen 
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Fig.No.7: UV Spectrum of Esomeprazole 
 
Fig.No.8: UV Spectrum of Isobestic Standard & Individual Standard  
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Beers - Lamberts Law 
Beers Law:- It  states that a similar relationship holds between transmittance and the 
concentration of solution i.e. the intensity of abeam of monochromatic light decreases 
exponentially with the increase in concentration of the absorbing substance arithmetically. 
There exist a relationship between the absorbance (A), transmittance (T) and the molar 
absorption coefficient () i.e. 
A=    ct = log I0/It =log 1/T = -logT 
Lamberts law:- It states that when a beam of light is allowed to pass through a transparent 
medium, the rate of decrease of intensity with the thickness of medium is directly 
proportional to the intensity of the light. 
Mathematical lamberts law stated as:-      
Where, 
 I - Intensity of incident light of wavelength  
 T - Thickness of the medium 
K - Proportionality factor 
Resemblance of Beers law to Naproxen: 
Concentration(ppm) Absorbance at 272 nm 
0 0 
15 0.278 
20 0.372 
25 0.472 
30 0.562 
40 0.745 
Table No. 10 : Linearity of Naproxen 
 
Fig.No.9: Linearity of Naproxen 
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Resemblance of Beers law to Esomeprazole: 
Concentration(ppm) Absorbance at 302 nm 
0 0 
12 0.493 
16 0.652 
20 0.809 
24 0.979 
32 1.309 
Table No. 11 : Linearity of Esomeprazole magnesium 
 
Fig.No.10: Linearity of Esomeprazole magnesium 
 
Naproxen obeys Beers law in the range of 0-40 ppm and shows the R
2
 = 0.999. 
Esomeprazole magnesium obeys Beers law in the range of 0-32 ppm and shows the 
R
2
 = 0.999. 
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5.3 Estimation of Naproxen and Esomeprazole magnesium in Tablet 
Formulation Form by RP-HPLC: 
Based on sample solubility, stability and suitability, various mobile phases 
compositions were tried to get a good resolution and sharp peak. 
The standard solution containing mixture of NAP and ESO as well as individual 
drugs were run in different mobile phases. 
The following trail were performed 
Preparation of Phosphate Buffer 
Preparation of 1.0 M Monobasic Sodium Phosphate Buffer: 
 Weigh accurately about 11.998 g of Monobasic Sodium Phosphate and transfer into 
100 mL    beaker and dilute up to the volume with water, and mix well. 
Preparation of 0.5 M Dibasic Sodium Phosphate Buffer: 
 Weigh accurately about 8.90 g of Dibasic Sodium Phosphate and transfer into 100 
mL beaker and dilute up to the volume with water, and mix well. 
Preparation Buffer solution: 
Prepare a Phosphate buffer by mixing 10.5 mL of 1.0 M monobasic sodium 
phosphate buffer and 60 mL of 0.5 M dibasic sodium phosphate buffer transfer into 1000 
mL beaker, and dilute up to the volume with water. Mixed and adjust the required pH with 
Ortho Phosphoric acid or Sodium Hydroxide. 
Trail-1 
Chromatographic Conditions: 
Parameter/Conditions Description/Values 
Column Name C18column(ODS,150mm×4.6 mm×5ȝm) 
Flow rate 1 mL 
Injection volume 20 µL 
Wavelength 302 nm 
Mobile phase pH 3.8Po4Buffer:ACN:Water (50:35:25) 
Table No.12:Chromatograpic Condition of Trail-1 
Fig.No.11:  Chromatogram of Trail-1 
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Observation:
 
 
 
Conclusion: Peak shape is not sharp.USP Plate count of Naproxen & Esomeprazole is 
also below the limit. (i.e. 2000). 
 
Trail - 2 
Chromatographic Conditions: 
Parameter/Conditions Description/Values 
Column Name C18column(ODS,150mm×4.6 mm×5ȝm) 
Flow rate 1 mL 
Injection volume 20 µL 
Wavelength 302 nm 
Mobile phase pH 4.2Po4 Buffer:ACN:Water (50:35:15) 
Table No.13:Chromatograpic Condition of Trail-2 
Fig.No.12:  Chromatogram of Trail-2 
Observation: 
 
 
Conclusion: USP Plate count of Naproxen & Esomeprazole is also below the limit. 
(i.e.2000). 
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Trail - 3 
Chromatographic Conditions: 
Parameter/Conditions Description/Values 
Column Name C18column(ODS,250mm×4.6 mm×5ȝm) 
Flow rate 1 mL 
Injection volume 20 µL 
Wavelength 302 nm 
Mobile phase pH 5.3Po4 Buffer:ACN:Water (40:50:10) 
Table No.14:Chromatograpic Condition of Trail-3 
Fig.No.13:  Chromatogram of Trail-3 
Observation: 
 
 
Conclusion: USP tailing factor of Naproxen & Esomeprazole is also above the limit. 
(i.e. <2.0). 
 
Trail - 4 
Chromatographic Conditions: 
Parameter/Conditions Description/Values 
Column Name C18column(ODS,250mm×4.6 mm×5ȝm) 
Flow rate 1 mL 
Injection volume 20 µL 
Wavelength 302 nm 
Mobile phase pH 4.2Po4 Buffer:ACN:Water (30:50:20) 
Table No.15:Chromatograpic Condition of Trail-4 
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Fig.No.14:  Chromatogram of Trail-4 
Observation: 
 
 
Conclusion: Peak Elution is not proper. Also Peak shape is not proper. 
 
Trail - 5 
Chromatographic Conditions: 
Parameter/Conditions Description/Values 
Column Name C18column(ODS,250mm×4.6 mm×10ȝm) 
Flow rate 1 mL 
Injection volume 20 µL 
Wavelength 302 nm 
Mobile phase pH 7.0Po4Buffer:ACN:Water (50:35:15) 
Table No.16:Chromatograpic Condition of Trail-5 
Fig.No.15:  Chromatogram of Trail-5 
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Observation: 
 
 
Conclusion: Peak Elution is not proper. Also Peak shape is not proper. 
 
Trail - 6 
Chromatographic Conditions: 
Parameter/Conditions Description/Values 
Column Name C18column(300mm×4.6 mm×5ȝm) 
Flow rate 1 mL 
Injection volume 20 µL 
Wavelength 302 nm 
Mobile phase pH 7.3Po4Buffer:ACN:Water (40:45:15) 
Table No.17:Chromatograpic Condition of Trail-6 
Fig.No.16:  Chromatogram of Trail-6 
 
Observation: 
 
 
Conclusion: USP tailing factor of Naproxen & Esomeprazole is also above the limit. 
( i.e.<2.0). 
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Trail - 7 
Chromatographic Conditions: 
Parameter/Conditions Description/Values 
Column Name C18column(300mm×4.6 mm×5ȝm) 
Flow rate 1 mL 
Injection volume 20 µL 
Wavelength 302 nm 
Mobile phase pH 7.3Po4Buffer:ACN:Water (50:35:15) 
Table No.18:Chromatograpic Condition of Trail-7 
Fig.No.17:  Chromatogram of Trail-7 
 
Observation: 
 
 
Conclusion: Peak Elution is not proper. Also Peak shape is not proper. 
 
Trail - 8 
Chromatographic Conditions: 
Parameter/Conditions Description/Values 
Column Name C18column(250mm×4.6 mm×5ȝm) 
Flow rate 1 mL 
Injection volume 20 µL 
Wavelength 302 nm 
Mobile phase pH 7.3Po4Buffer:ACN:Water (50:35:15) 
Table No.19:Chromatograpic Condition of Trail-8 
 
 
47 
                                                                       
 
 
Fig.No.18:  Chromatogram of Trail-8 
 
Observation: 
 
 
Conclusion:  Tailing factor was <2.0, Resolution was optimum and Plate count was >2000, 
so this method is considered as the optimized method. 
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CHAPTER 6 
6.1 METHOD VALIDATION 
Preparation of 1M monobasic sodium phosphate buffer: 
 Weighed accurately 11.998 g of monobasic sodium phosphate anhydrous and 
transferred into 100 mL volumetric flask, and dilute up to the volume with water. 
 
Preparation of 0.5M dibasic sodium phosphate buffer: 
 Weighed accurately 7.10 g of dibasic sodium phosphate anhydrous and transferred 
into 100 mL volumetric flask, and dilute up to the volume with water. 
 
Prepare of 1M sodium hydroxide: 
 Weighed accurately 4.0 g of sodium hydroxide and transferred into 100 mL 
volumetric flask, and dilute up to the volume with water. 
 
Prepare of 1M phosphoric acid: 
 Pipette out 6.4 mL of ortho phosphoric acid and transferred into 100 mL volumetric 
flask, and dilute up to the volume with water. 
 
Prepare of pH 7.3 phosphate buffer for mobile phase: 
 Prepared a mixture 10.5 mL of 1M mono basic sodium phosphate buffer and 60 mL 
of 0.5M dibasic sodium phosphate buffer, and dilute with water to 1000 mL Adjusted pH to 
7.3 with 1M sodium hydroxide or 1M phosphoric acid. 
 
Preparation of Mobile Phase: 
 Prepared a mixture 350 volume of Acetonitrile, 500 volume of pH 7.3 buffer 
solution and 150 volume of water. Filtered the solution 0.45 µm nylon filter and sonication 
was done for 10 minutes. 
 
Preparation of diluents: 
 Water: Methanol (50:50) v/v. 
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Procedure for preparation of analytical solutions: 
Preparation of standard stock solution A (100 mcg/mL of Esomeprazole): 
 Weighed accurately 20.65 mg of Esomeprazole magnesium WS (Equivalent to 20 mg 
Esomeprazole) and transferred into a 200 mL volumetric flask. Added 100 mL of diluent 
and sonication was done for 5 minutes to dissolve. Cooled and diluted up to the volume 
with diluent. 
Preparation of standard stock solution B (2500 mcg/mL of Naproxen): 
 Weighed accurately 137.0 mg of Naproxen Sodium WS (Equivalent to 125 mg of 
Naproxen) and transferred into a 50 mL volumetric flask. Added 25 mL of diluent and 
sonication was done for 5 minutes to dissolve. Cooled and diluted up to the volume with 
diluent.  
Preparation of standard solution (20 mcg/mL of Esomeprazole and 500 mcg/mL of 
Naproxen): 
 Transferred 5 mL of the each stock solution A and 5 mL of the each stock solution B 
through pipette into a 25 mL volumetric flask and diluted up to the volume with mobile 
phase and mixed well. Filtered the solution through 0.45 µm Nylon filter and collected the 
solution in an HPLC vial after discarded the first 2 mL of filtrate. 
Sample solution (20 mcg/mL of Esomeprazole and 500 mcg/mL of Naproxen): 
 Weighed and finely powder not fewer than 20 tablets. Transferred an accurately 
weighed portion of the powder, equivalent to about 20 mg of Esomeprazole and 500 mg of 
Naproxen into a 100 mL volumetric flask. Added 50 mL of diluent and sonication was for 
15 minutes to dissolve. Cooled and diluted up to the volume with diluent. Transferred 5 mL 
of this above solution through pipette into a 50 mL volumetric flask and diluted up to the 
volume with mobile phase and mix. Filtered the solution through 0.45 µm Nylon filter and 
collected the solution in an HPLC vial after discarded the first 2 mL of filtrate. 
Placebo solution: 
 Weighed accurately 587 mg of Esomeprazole magnesium and Naproxen tablet placebo 
and transferred into 100 mL volumetric flask. Added 50 mL of diluent and sonication was 
done for 15 minutes to dissolve. Cooled and diluted up to the volume with diluent. 
Transferred 5 mL of this above solution through pipette into a 50 mL volumetric flask and 
diluted up to the volume with mobile phase and mixed well. Filtered the solution through 
0.45 µm Nylon filter and collected the solution in an HPLC vial after discarded the first 2 
mL of filtrate. 
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CALCULATIONS: 
 
Content of Esomeprazole in  mg:  
    SPL Area    STD wt in mg       5        100            50     STD Purity in ASB      690.83 
=---------------x-------------------x------x-----------x--------x-------------------------x------------x Avg .Wt. 
    STD Area           200               25      SPL Wt       5                   100                   713.12     
  
=690.83 is a molecular weight of Esomeprazole.  
=713.12 is a molecular weight of Esomeprazole magnesium Anhydrous.  
 
Content of Esomeprazole in  %:  
    Esomeprazole in mg 
= -------------------------------------------------- x 100 
    Label claim of Esomeprazole tablet in mg 
 
Acceptance Criteria: 
 18.0 mg to 22.0 mg (90.0 % to 110.0 % of label claim) 
 
Content of Naproxen in  mg:  
    SPL Area      STD wt in mg       5          100          50      STD Purity in ASB       230.26 
=---------------x------------------x------x-----------x-------x--------------------------x-----------x Avg. Wt. 
    STD Area          50                    25      SPL Wt.      5                 100                      252.24     
 
= 230.26 is a molecular weight of Naproxen.  
= 252.24 is a molecular weight of Naproxen Sodium.  
 
Content of Naproxen in  %:  
               Naproxen in mg 
= ------------------------------------------------- x 100 
        Label claim of Naproxen in tablet in mg 
 
Acceptance Criteria: 
 450.0 mg to 550.0 (90.0 % to 110.0 % of label claim) 
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Chromatographic Conditions: 
 
Parameter/Conditions Description/Values 
Column Name C18column(250mm×4.6 mm×5ȝm) 
Flow rate 1 mL 
Injection volume 20 µL 
Wavelength 302 nm 
Mobile phase pH 7.3Po4Buffer:ACN:Water (50:35:15) 
Table No.20:Chromatograpic Condition of Optimized method 
System Suitability requirement: 
1) The resolution of the peaks obtained for six replicates standard solution injections 
between Naproxen  and Esomeprazole  should be not less than 3.0 
2) The tailing factor of the peaks obtained for six replicates standard solution 
injections of Naproxen and Esomeprazole should be not more than 2.0. 
3) The relative standard deviation of the area obtained for six replicates standard 
solution of Naproxen and Esomeprazole should be not more than 2.0 %. 
4) Theoretical plates of the peaks obtained for six replicates standard solution 
injections of Naproxen and Esomeprazole should be not less than 2000. 
1. Precision 
The precision of an analytical procedure expresses the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple sampling of 
the same homogeneous sample under the prescribed conditions. 
Precision may be considered at three levels:  
a) System Precision (Repeatability) 
b) Method Precision (Reproducibility) 
c) Intermediate precision (Ruggedness) 
The precision of an analytical procedure is usually expressed as the variance, 
standard deviation or coefficient of variation of a series of measurements. A minimum of 6 
replicate sample determinations should be made together with a simple statistical 
assessment of the results, including the percent relative standard deviation. The following 
levels of precision are recommended. 
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a) System Precision (Repeatability) 
Determine the closeness of agreement of the same homogenous standard 
preparations under the prescribed conditions. Six replicate injections were injected into the 
HPLC system. The % RSD for the peak responses of six replicate injections should be 
NMT 2.0. 
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Fig.No.19: Chromatogram of System precision 
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Peak Results for System Precision 
Naproxen Esomeprazole magnesium 
Inj. RT 
(min)
Area 
(μV*sec) 
Inj. RT 
(min) 
Area 
(µV*sec) 
1 3.393 89104756 1 8.147 109097952 
2 3.393 89041992 2 8.147 108993605 
3 3.400 89123222 3 8.147 109015747 
4 3.393 89145254 4 8.140 109024679 
5 3.400 89122794 5 8.147 109029797 
6 3.400 89138970 6 8.147 108908594 
Mean 89112831 Mean 109011729 
% RSD 0.042 % RSD 0.056 
Table No.21:Peak Result for System Precision 
Data Interpretation 
It is observed from the data tabulated above, that the % RSD of the peak responses 
as peak area was found to be within acceptance criteria indicating an acceptance level of 
precision for system precision studies. 
b) Method Precision (Reproducibility) 
In method precision, a homogenous sample of a single batch should be analysed 
six times. This indicates whether a method is giving consistent results for a single 
batch. The % RSD for the six determinations should be NMT 2.0. 
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Fig.No.20: Chromatogram of Method precision 
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Method Precision Results for Naproxen 
Test No Sample-1 Sample-2 Sample-3 Sample-4 Sample-5 Sample-6 
Avg.wt (in mg) 1156.37 
Wt.taken (in mg) 1159.21 1158.48 1159.42 1159.06 1159.36 1158.27 
Area(Injection-1) 87178270 87240756 87462405 87366231 87772791 87344466 
Area(Injection-2) 87178986 87254969 87475855 87398182 87954872 87285843 
Mean 87178628 87247863 87469130 87382207 87863832 87315155 
STDV 1.354    
%RSD 0.262 
Table No.22:Method Precision Result for Naproxen 
Method Precision Results for Esomeprazole magnesium 
Test No Sample-1 Sample-2 Sample-3 Sample-4 Sample-5 Sample-6 
Avg.wt (in mg) 1156.37 
Wt.taken (in mg) 1159.21 1158.48 1159.42 1159.06 1159.36 1158.27 
Area(Injection-1) 
119867586 119930122 119828973 119872459 119812111 119775234
Area(Injection-2) 
119884786 119834075 119895431 119002620 119853347 119770953 
Mean 
119876186 119882099 119862202 119437540 119832729 119773094 
STDV 0.032     
%RSD 0.157 
Table No.23:Method Precision Result for Esomeprazole magnesium 
Data Interpretation: From the above results, it was concluded that the method is precise. 
2. Linearity 
The linearity of an analytical method is its ability to elicit test results that are 
directly, or by a well-defined mathematical transformation, proportional to the 
concentration of analyte in samples within a given range. A series of standard 
concentrations were prepared from 60%, 80%, 100%, 120% &160% of the targeted 
concentration of both Naproxen and Esomeprazole magnesium. A linearity graph of 
concentration (ȝg/ml) versus average area response was plotted for Naproxen and 
Esomeprazole magnesium peaks and the correlation coefficient was calculated. The 
correlation coefficient should be NLT 0.999. 
Preparation of standard stock solution A (100 mcg/mL of Esomeprazole): 
 Weigh accurately about 20.65 mg of Esomeprazole magnesium WS (Equivalent to 20 
mg Esomeprazole) and transfer into a 200 mL volumetric flask. Add about 100 mL of 
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diluent and sonicate for 5 minutes to dissolve. Cool and dilute up to the volume with 
diluent. 
Preparation of standard stock solution B (2500 mcg/mL of Naproxen): 
Weigh accurately about 137.0 mg of Naproxen Sodium WS (Equivalent to 125 mg 
of Naproxen) and transfer into a 50 mL volumetric flask. Add about 25 mL of diluent and 
sonicate for 5 minutes to dissolve. Cool and dilute up to the volume with diluent. 
Preparation of Linearity Dilution for Naproxen and Esomeprazole magnesium: 
Linearity 
Level(%) 
Volume of 
Stock Taken 
(mL) 
Diluted 
to (mL) 
Naproxen 
Conc.(mcg/mL) 
Esomeprazole 
magnesium 
Conc.(mcg/mL) 
60 3 25 12 300 
80 4 25 16 400 
100 5 25 20 500 
120 6 25 24 600 
160 8 25 32 800 
Table No.24:Linearity dilution for Naproxen and Esomeprazole magnesium 
Fig.No.21: Chromatogram for Linearity at 60% 
Fig.No.22: Chromatogram for Linearity at 80% 
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Fig.No.23: Chromatogram for Linearity at 100% 
Fig.No.24: Chromatogram for Linearity at 120% 
Fig.No.25: Chromatogram for Linearity at 160% 
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Calculation for Linearity of Naproxen 
Linearity 
Level 
Conc(mcg/mL) Area 
(Injection-1) 
Area 
(Injection-2) 
Average 
60 300 53087978 53120909 53104444 
80 400 70853430 70938599 70896015 
100 500 90124646 90341412 90233029 
120 600 107228155 107404925 107316540 
160 800 140669395 141002883 140836139 
Correlation coefficient 0.999 
Slope 175839.7448 
Y Intercept 1040565.905 
% Y-intercept 0.969623047 
Table No.25:Linearity Calculation for Naproxen 
Fig.No.26: Linearity Plot of Naproxen 
Linearity Calculation for Esomeprazole magnesium 
Linearity 
Level 
Conc(mcg/mL) Area 
(Injection-1) 
Area 
(Injection-2) 
Average 
60 12 64891655 64972888 64932272 
80 16 83209664 83151599 83180632 
100 20 104922648 105028486 104975567 
120 24 126580317 126694766 126637542 
160 32 169350156 169364758 169357457 
Correlation coefficient 0.999 
Slope 5267703.451 
Y Intercept 248461.9189 
% Y-intercept 0.19619926 
Table No.26:Linearity Calculation for Esomeprazole magnesium 
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Fig.No.27: Linearity Plot of Esomeprazole magnesium 
Data Interpretation 
The Correlation coefficient for Naproxen and Esomeprazole magnesium was found 
to be 0.999 and 0.999 respectively, which indicates that the peak responses are linear. This 
concluded that the method was linear throughout the range selected. 
3. Accuracy 
The accuracy of an analytical method is the closeness of test results obtained by that 
method to the true value. The accuracy study was conducted by spiking the known amount 
of active ingredients into the placebo at three different levels (50%, 100% and 150% of 
target concentration). The samples were analysed as per the proposed test procedure and 
the % recovery for each spiked level was calculated. 
The % RSD at each spike level should be NMT 2.0. The overall % RSD for % 
recovery for all spike level should be NMT 2.0. The % recovery at each spike level should 
be NLT 98.0 and NMT 102.0 of the added amount. 
 
Procedure for Accuracy 
 
Placebo spiked with 50% standard solution preparation (10 mcg/mL of Esomeprazole 
and 250 mcg/mL of Naproxen): 
Weigh accurately about 10.33 mg of Esomeprazole magnesium WS (Equivalent to 
10 mg Esomeprazole), and 273.86 mg of Naproxen Sodium (Equivalent to 250 mg of 
Naproxen), and transfer into a 100 mL volumetric flask. Add about 293.5 mg of Naproxen 
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and Esomeprazole magnesium Tablet Placebo and 50 mL of diluent, and sonicate for 15 
minutes to dissolve. Cool and dilute up to the volume with diluent. Transfer 5 mL of this 
above solution through pipette into a 50 mL volumetric flask and dilute up to the volume 
with mobile phase and mix. Filter the solution through 0.45 µm Nylon filter and collect the 
solution in an HPLC vial after discarding about first 2 mL of filtrate. 
 
Placebo spiked with 100% standard solution preparation (20 mcg/mL of 
Esomeprazole and 500 mcg/mL of Naproxen): 
Weigh accurately about 20.65 mg of Esomeprazole magnesium WS (Equivalent to 
20 mg Esomeprazole), and 547.73 mg of Naproxen Sodium (Equivalent to 500 mg of 
Naproxen), and transfer into a 100 mL volumetric flask. Add about 587 mg of Naproxen 
and Esomeprazole magnesium Tablet Placebo and 50 mL of diluent, and sonicate for 15 
minutes to dissolve. Cool and dilute up to the volume with diluent. Transfer 5 mL of this 
above solution through pipette into a 50 mL volumetric flask and dilute up to the volume 
with mobile phase and mix. Filter the solution through 0.45 µm Nylon filter and collect the 
solution in an HPLC vial after discarding about first 2 mL of filtrate. 
 
Placebo spiked with 150 % standard solution preparation (30 mcg/mL of 
Esomeprazole and 750 mcg/mL of Naproxen): 
Weigh accurately about 30.97 mg of Esomeprazole magnesium WS (Equivalent to 
30 mg Esomeprazole), and 821.60 mg of Naproxen Sodium (Equivalent to 750 mg of 
Naproxen), and transfer into a 100 mL volumetric flask. Add about 880.5 mg of Naproxen 
and Esomeprazole magnesium Tablet Placebo and 50 mL of diluent, and sonicate for 15 
minutes to dissolve. Cool and dilute up to the volume with diluent. Transfer 5 mL of this 
above solution through pipette into a 50 mL volumetric flask and dilute up to the volume 
with mobile phase and mix. Filter the solution through 0.45 µm Nylon filter and collect the 
solution in an HPLC vial after discarding about first 2 mL of filtrate. 
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Fig.No.28: Chromatogram for Accuracy at 50% level 
Fig.No.29: Chromatogram for Accuracy at 100% level 
Fig.No.30: Chromatogram for Accuracy at 150% level 
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Results for Accuracy of Naproxen 
 
Concentration 
Spiked 
Std 
(mg) 
Area Inj-1 Area Inj-2 Avg. Area Recovered 
Std 
(mg) 
Amt 
Recovered 
(%) 
Mean of 
% 
Recovered 
 
50 
273.93 44962664 44025661 44494163 273.230 99.74  
99.83 274.06 44871445 44303910 44587678 273.804 99.91 
 
100 
547.91 88907136 88978636 88942886 546.180 99.68  
99.68 548.13 88960179 88970438 88965309 546.318 99.67 
 
150 
821.76 132885170 132946970 132916070 816.211 99.32  
99.33 821.64 132924809 132920805 132922807 816.252 99.34 
Overall Recovery 99.61 
Table No.27: Peak Results for Accuracy of Naproxen 
 
Results for Accuracy of Esomeprazole magnesium 
 
Concentration 
Spiked 
Std 
(mg) 
Area Inj-1 Area Inj-2 Avg. Area Recovered 
Std 
(mg) 
Amt 
Recovered 
(%) 
Mean of 
% 
Recovered 
 
50 
10.50 54598780 54596647 54597714 10.436 99.39  
99.83 10.40 54542550 54565139 54553845 10.428 100.27 
 
100 
20.71 108351302 108354041 108352672 20.712 100.01  
99.90 20.75 108326424 108312606 108319515 20.706 99.79 
 
150 
31.03 162861284 161164468 162012876 30.969 99.80  
99.75 31.07 161970148 162105020 162037584 30.974 99.69 
Overall Recovery 99.83 
Table No.28: Peak Results for Accuracy of Esomeprazole magnesium 
Data Interpretation 
 The results were found within acceptance criteria. Hence the method is accurate 
throughout the selected range. 
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4. Specificity 
Blank & Placebo Interference: Placebo was injected by weighing the equivalent 
amount present in the finished drug product and analysed for interference due to placebo. 
Fig.No.31: Chromatogram of Blank 
Fig.No.32: Chromatogram of Placebo 
Data Interpretation 
On the basis of these chromatograms we can say that there is no interference of 
blank and placebo at the retention time of Naproxen and Esomeprazole magnesium. Hence 
the method is specific. 
5. Intermediate Precision (Ruggedness) 
 Intermediate precision expresses within-laboratories variations: different days, 
different analysts, different equipment, etc. 
 Intermediate precision is to be performed by different analyst coupled with different 
day. The % RSD for the six determinations should be NMT 2.0. 
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Fig.No.33: Chromatogram of Intermediate precision 
Intermediate Precision Results for Naproxen 
Test No Sample-1 Sample-2 Sample-3 Sample-4 Sample-5 Sample-6 
Avg.wt (in mg) 1156.37 
Wt.taken (in mg) 1159.16 1159.24 1159.36 1158.09 1157.36 1156.13 
Area(Injection-1) 
87097682 87154613 87096407 87098788 87092407 87076030 
Area(Injection-2) 
87097891 87095231 
87093570 87092879 87091153 87076945 
Mean 87097787 87124922 87094989 87095834 87091780 87076488 
%RSD 0.099    
Table No.29: Intermediate Precision result for Naproxen 
Intermediate Precision Results for Esomeprazole magnesium 
Test No Sample-1 Sample-2 Sample-3 Sample-4 Sample-5 Sample-6 
Avg.wt (in mg) 1156.37 
Wt.taken (in mg) 1159.16 1159.24 1159.36 1158.09 1157.36 1156.13 
Area(Injection-1) 113630040 113102780 113957873 113736070 113702174 113817901 
Area(Injection-2) 113514693 113234171 113971749 113840069 113662524 113785272 
Mean 113572367 113168476 113964811 113788070 113682349 113801587 
%RSD 0.298    
Table No.30: Intermediate Precision result for Esomeprazole magnesium 
 
 
67 
                                                                       
 
 
Data Interpretation: System suitability result passes and the results obtained for 
Intermediate precision are found within the acceptance criteria. 
6. ROBUSTNESS: 
The Robustness for the analytical procedure expresses a measure of its capacity to 
remain unaffected by small, but deliberate variations in method parameters and provides an 
indication of its reliability during analysis. 
a) Change in flow rate plus (1.2 mL/minute): 
For Chromatographic conditions, follow the method of analysis given in the Table 
No.20 except by changing the flow to 1.2 mL / minute instead of 1.0 mL / minute. 
b) Change in flow rate minus (0.8 mL/minute): 
For Chromatographic conditions, follow the method of analysis given in the Table 
No.20 except by changing the flow to 0.8 mL / minute instead of 1.0 mL / minute. 
c) Change in wavelength plus (304 nm): 
For Chromatographic conditions, follow the method of analysis given in the Table 
No.20 except by changing the wavelength to 304 nm instead of 302 nm. 
d) Change in wavelength minus (300 nm): 
For Chromatographic conditions, follow the method of analysis given in the Table 
No.20 except by changing the wavelength to 300 nm instead of 302 nm. 
e) Change in mobile phase organic content plus (+5%): 
 Change the least organic solvents ratio to 36.5 volumes instead of 35 volume, and 
adjust the quantity variation from Buffer concentration to maintain 100 %. Maintain other 
chromatographic condition remains same as given in the Table No.20. 
f) Change in mobile phase organic content minus (-5%): 
 Change the least organic solvents ratio to 33.25 volumes instead of 35 volumes, 
and adjust the quantity variation from Buffer concentration to maintain 100%. Maintain 
other chromatographic condition remains same as given in the Table No.20. 
 
 
 
 
 
 
 
 
 
68 
                                                                       
 
 
System suitability results for Naproxen: 
S. 
No. 
Parameter Name 
Naproxen Results obtained 
Tailing factor  Area (RSD) Theoretical Plates
01 
Change in wavelength Plus 
304nm 
1.65 0.451 8331 
02 
Change in wavelength Minus 
300 nm 
1.57 0.049 8174 
03 Change in Flow rate 0.80 mL 1.56 0.318 10625 
04 Change in Flow rate 1.20 mL 1.84 0.026 6992 
05 Change in Mobile phase  plus 1.10 0.304 12060 
06 Change in Mobile phase minus 1.34 0.161 5801 
Acceptance criteria NMT 2.0  
NMT 
2.0% 
NLT 1000 
Table No.31: System Suitability result for Naproxen 
System suitability results for Esomeprazole magnesium: 
S. 
No. 
Parameter Name 
Esomeprazole magnesium Results obtained 
Tailing factor Area (RSD) Theoretical Plates
01 
Change in wavelength Plus 
304nm 
1.06 0.094 7329 
02 
Change in wavelength Minus 300 
nm 
1.06 0.101 7328 
03 Change in Flow rate 0.80 mL 0.83 0.135 8564 
04 Change in Flow rate 1.20 mL 1.00 0.980 6696 
05 Change in Mobile phase  plus 1.74 0.161 6585 
06 Change in Mobile phase minus 0.98 0.071 8008 
Acceptance criteria NMT 2.0  
NMT 
2.0% 
NLT 1000 
Table No.32: System Suitability result for Esomeprazole magnesium 
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Robustness results obtained for Naproxen: 
 S. 
No. 
Parameter Name 
Results obtained 
Acceptance 
criteria 
Naproxen drug 
in mg 
Naproxen drug 
in % 
1 
Robust Wavelength 304 
nm 
499.76 99.95 
 
9
0
.0
%
 -
 1
1
0
.0
%
 
 
2 
Robust Wavelength 300 
nm 
503.12 100.62 
3 Robust flow rate 0.8 mL 499.75 99.95 
4 Robust flow rate 1.2 mL 501.91 100.38 
5 
Robust mobile phase  
composition +5 % 
501.48 100.38 
6 
Robust mobile phase  
composition  -5 % 
501.40 100.28 
Table No.33: Robustness result for Naproxen 
Robustness results obtained for Esomeprazole: 
 S. No. Parameter Name 
Results obtained 
Acceptance 
criteria 
Esomeprazole 
drug in mg 
Esomeprazole 
drug in % 
1 
Robust Wavelength 304 
nm 
19.90 99.50 
 
9
0
.0
%
 -
 1
1
0
.0
%
 
 
2 
Robust Wavelength 300 
nm 
19.93 99.65 
3 Robust flow rate 0.8 mL 19.99 99.95 
4 Robust flow rate 1.2 mL 19.84 99.20 
5 
Robust mobile phase  
composition +5 % 
20.10 100.50 
6 
Robust mobile phase  
composition  -5 % 
19.90 99.50 
Table No.34: Robustness result for Esomeprazole magnesium 
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Combined Method precision and Robustness results obtained for Naproxen: 
S. No. Parameter Name 
Results obtained 
Drug in 
mg 
Drug  in % 
Acceptance 
criteria 
01 Method precision – 1 509.53 101.91 
9
0
.0
%
-1
1
0
.0
%
 
02 Method precision – 2 509.67 101.93 
03 Method precision – 3 509.38 101.88 
04 Method precision – 4 509.62 101.92 
05 Method precision – 5 509.38 101.88 
06 Method precision – 6 509.87 101.97 
07 Robust Wavelength 304 nm 499.76 99.95 
08 Robust Wavelength 300 nm 503.12 100.62 
09 Robust flow rate 0.8 mL 499.75 99.95 
10 Robust flow rate 1.2 mL 501.91 100.38 
11 
Robust mobile phase  
composition +5 % 
 501.48 100.30 
12 
Robust mobile phase  
composition  -5 % 
501.40 100.28 
Mean 101.08 
Std Dev 0.889 
NMT 2.0% 
% RSD 0.879 
Table No.35: Combined Method precision and Robustness result for Naproxen 
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Combined method precision and Robustness results obtained for Esomeprazole 
magnesium: 
S. No. Parameter Name 
Results obtained 
Drug in 
mg 
Drug  in % 
Acceptance 
criteria 
01 Method precision – 1 20.23 101.15 
9
0
.0
%
-1
1
0
.0
%
 
02 Method precision – 2 20.15 100.75 
03 Method precision – 3 20.21 101.05 
04 Method precision – 4 20.12 100.60 
05 Method precision – 5 20.24 101.20 
06 Method precision – 6 20.14 100.70 
07 Robust Wavelength 304 nm 19.90 99.50 
08 Robust Wavelength 300 nm 19.93 99.65 
09 Robust flow rate 0.8 mL 19.99 99.95 
10 Robust flow rate 1.2 mL 19.84 99.20 
11 
Robust mobile phase  
composition +5 % 
20.10 100.50 
12 
Robust mobile phase  
composition  -5 % 
19.90 99.50 
Mean 100.31 
Std Dev 0.715 
NMT 2.0% 
% RSD 0.713 
Table No.36: Combined Method precision and Robustness result for Esomeprazole 
magnesium 
Data Interpretation 
System suitability result passes in all the deliberately changed methods and the results 
obtained for all deliberately changed methods are found within the acceptance criteria. 
Combined deliberately changed methods results and method precision results are found 
within the desirable limit. It is concluded that the deliberately changed assay methods 
results are remains unaffected in small variations. 
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7. Solution Stability 
Solution stability for Naproxen 
Standard Sample 
Time Area Average % RSD Area Average % RSD 
0 hrs 89227132 NA NA 87348145 NA NA 
3 hrs 89077564 89152348 0.119 87232593 87290369 0.094 
6 hrs 89044890 89116529 0.109 87254199 87278312 0.070 
9 hrs 89950958 89325136 0.475 87378416 87303338 0.081 
12 hrs 89056712 89271451 0.433 87288925 87300456 0.071 
15 hrs 89272542 89271633 0.388 87565638 87344653 0.139 
18 hrs 89272580 89271768 0.354 87670265 87391169 0.190 
21 hrs 89685749 89323516 0.366 87930200 87458548 0.280 
24 hrs 89932554 89391187 0.411 87851935 87502257 0.301 
Table No.37: Solution Stability for Naproxen 
Solution stability for Esomeprazole magnesium 
Standard Sample 
Time Area Average % RSD Area Average % RSD 
0 hrs 104820179 NA NA 118471614 NA NA 
3 hrs 104739579 104779879 0.054 118311525 118391570 0.096 
6 hrs 104619981 104726580 0.096 118372713 118385284 0.068 
9 hrs 104557597 104684334 0.113 118414551 118392601 0.057 
12 hrs 104670188 104681505 0.098 118198942 118353869 0.088 
15 hrs 104614098 104670270 0.091 118098321 118311278 0.118 
18 hrs 104119947 104591653 0.216 117779367 118235290 0.202 
21 hrs 104336847 104559802 0.218 117791135 118179771 0.229 
24 hrs 104344670 104535898 0.215 117402039 118093356 0.307 
Table No.38: Solution Stability for Esomeprazole magnesium 
Data Interpretation 
System suitability result passes and the results obtained for stability of standard 
solution and sample solution are found within the acceptance criteria for the minimum 
period of 24 hours study. Hence, it is concluded that the standard solution and sample 
solution as mentioned in the assay method are capable to inject into the chromatography 
within 24 hours from the time of preparations. 
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CHAPTER 7 
RESULT AND DISCUSSION   
The objective of the proposed work was method development for the simultaneous 
estimation of Naproxen and Esomeprazole magnesium in tablets by RP-HPLC and to 
validate the developed method according to USP and ICH guidelines and applying the 
same for use in the quality control samples in pharmaceutical industry. 
As there is no official method for the simultaneous estimation of Naproxen and 
Esomeprazole magnesium in this selective combination, so we tried to develop a method 
by which we can quantify the amount of drug present in the given sample.  
  In RP-HPLC method, the conditions were optimized to obtain an adequate 
separation of eluted compounds. Initially, various mobile phase compositions were tried, to 
separate titled ingredients. Mobile phase and flow rate selection was based on peak 
parameters (height, tailing, theoretical plates, capacity or symmetry factor), run time and 
resolution. The system with pH7.3 Phosphate Buffer: ACN: Water (50:35:15) at flow rate 
of 1.0 ml/min
 
was found to be quite robust. 
The optimum wavelength for detection was 302 nm at which better detector 
response for both the drugs was obtained. The average retention times for Naproxen and 
Esomeprazole magnesium was found to be 3.397 and 8.146 min, respectively. According to 
United States Pharmacopeia, system suitability tests are an integral part of chromatographic 
method. They are used to verify the reproducibility of the chromatographic system. To 
ascertain its effectiveness, system suitability tests were carried out on freshly prepared 
stock solutions. The calibration was linear in various concentration range with correlation.  
The low values of RSD indicate that the method was precise and accurate. The 
mean recoveries were found in the range of 98 – 102 %. System precision is evaluated by 
injecting 6 injections of standard solution and low value of % RSD shows that system is 
precise. Precision for method is evaluated by analyzing a sample of homogenous batch six 
times and the low % RSD value shows the method is precise. 
Method robustness was evaluated by alteration of flow rate (±0.2 mL), Wavelength 
(± 2 nm), Mobile phase Organic Content (±5%) and it was found robust as % RSD was 
below 2.0%.  
Ruggedness of the proposed method was determined by analysis of aliquots from 
homogeneous slot in different laboratories, by different analysts, different column, different 
system using similar environmental conditions, the % R.S.D. reported was found to be less 
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than 2 %. The proposed method was validated in accordance with ICH parameters and the 
applied for analysis of the same in marketed formulations.  
Both sample solution and standard solution are stable at 25°C for 24 hrs. as the % 
difference in the RSD was found to be less than 2.0%. 
Finally, it can be concluded that the assay values of formulation were the same as 
mentioned in the label claim with the RSD of ≤ 2.0%.  
The proposed method was found to be accurate, precise, reproducible and stable, 
and can be successfully applied for the routine analysis of both the drugs in combined 
tablet dosage forms. 
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CHAPTER 8 
CONCLUSION 
An efficient high performance liquid chromatographic method was developed and 
validated for the simultaneous estimation of Naproxen and Esomeprazole magnesium. In 
RP-HPLC method, the conditions were optimized to obtain an adequate separation of 
eluted compounds. Initially, various mobile phase compositions were tried, to separate 
titled ingredients. Mobile phase and flow rate selection was based on peak parameters 
(height, tailing, theoretical plates, capacity or symmetry factor), run time and resolution. 
The system with pH 7.3 Phosphate buffer: ACN: Water at flow rate of 1.0 mL/min
 
was 
found to be quite robust. 
The low values of RSD indicate that the method was precise and accurate. The 
mean recoveries were found in the range of 98 – 102 %. System precision is evaluated by 
injecting 6 injections of standard solution and low value of % RSD shows that system is 
precise. Precision for method is evaluated by analysing a sample of homogenous batch six 
times and the low % RSD value shows the method precise. 
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CHAPTER 9 
SUMMARY 
 
Validation Parameter 
 
Acceptance Criteria 
Result 
Naproxen Esomeprazole 
magnesium 
 
 
Precision 
 
 
 
System 
 
The %RSD of  6 replicate 
injections should be ≤ 2.0% 
 
0.042 
 
0.056 
 
Method 
The% RSD calculated on 6 
determinations of assay value 
should be ≤ 2.0% 
 
0.262 
 
0.157 
Linearity The correlation coefficient 
should be ≥1.0 
0.99960 0.99964 
Accuracy The Overall % recovery for 
all spike level should be 
NLT 98.0 and NMT 102.0 
of the added amount. 
 
99.61 
 
99.83 
Specificity The peaks of diluents and 
placebo should not interfere 
with the main peaks 
The peaks of diluents and placebo 
did not interfering with the peaks 
of Naproxen and Esomeprazole 
magnesium. 
Intermediate Precision 
(Ruggedness) 
The% RSD calculated on 6 
determinations of assay value 
should be ≤ 2.0% 
 
0.099 
 
0.298 
 
 
Robustness 
Flow rate plus (1.2 mL) 0.026 0.980 
Flow rate minus (0.8 mL) 0.318 0.135 
Wavelength plus (304 nm) 0.451 0.094 
Wavelength minus (300 nm) 0.049 0.101 
Mobile phase organic 
content plus (+5%) 
0.304 0.161 
Mobile phase organic 
content minus (-5%) 
0.161 0.071 
Solution Stability RSD ≤ 2.0% 0.301 0.307 
Table No.39: Summery 
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